Faropenem, a highly efficacious and orally bioavailable beta-lactam antibiotic, exhibits an extensive range of in vitro antimicrobial activity against diverse gram-positive and -negative aerobes and anaerobes. Notably, Faropenem possesses inherent resistance to hydrolysis by virtually all beta-lactamases, including extended-spectrum beta-lactamases and AmpC beta-lactamases. Moreover, Faropenem has been developed as an oral prodrug, namely faropenem medoxomil, for the investigation of respiratory tract infections.

Faropenem is not active against methicillin-resistant Staphylococcus aureus , vancomycin-resistant Enterococcus faecium , Pseudomonas aeruginosa or Stenotrophomonas maltophilia[1].Faropenem is against all isolates?of B. anthracis .?The MIC values ranged from ≤0.06 to >64 μg/liter, and the MIC 90 value is 0.5 μg/ml. The MIC 90 value for Faropenem is lower than that observed for other β-lactams, such as Meropenem, Amoxicillin-clavulanate, and Penicillin, for which the MIC 90 values are 4 μg/ml, 4 μg/ml, and 8 μg/ml, respectively[2].

Faropenem ( i.p. at 24 h postchallenge at 4-, 6-, and 12-h intervals; 10, 20, 40, and 80 mg/kg/day; 14 days) demonstrates a high level of activity against B. anthracis in the murine post-exposure prophylaxis inhalation model[1].